Medscape www.medscape.com

References for:
Variability in Activity of Hepatic CYP3A4 in Patients Infected With HIV

[Pharmacotherapy 20(8):898-907, 2000. © 2000 Pharmacotherapy Publications]

  1. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
  2. Molla A, Korneyeva K, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996;2:760-6.
  3. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996;10:485-92.
  4. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999;19:708-12.
  5. Burger DM, Koopmans PP, Brinkman K, et al. Therapeutic drug monitoring of the HIV-protease inhibitor indinavir [abstr]. Presented at the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, September 28-October 1, 1997.
  6. Harris M, Durakovic C, Rae S, et al. Virologic response to indinavir/neviripine/3TC correlates to indinavir trough concentrations [abstr]. Presented at the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, September 28-October 1, 1997.
  7. Schapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
  8. Watkins PB. Drug metabolism by cytochrome P450 in the liver and small bowel. Gastroenterol Clin North Am 1992;21: 511-26.
  9. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochrome P-450. Studies in rats and patients. J Clin Invest 1989;83:688-97.
  10. Watkins PB. Erythromycin breath test and clinical transplantation. Ther Drug Monit 1996;18:368-71.
  11. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997;25:256-66.
  12. Chiba K, Hensleigh K, Lin JH. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes: major role of CYP3A. Biochem Pharmacol 1997;53:1187-95.
  13. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999;39:1203-11.
  14. Murphy RL, Sommadossi J-P, Lamson M, Hall DB, Myers M, Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with immunodeficiency virus type-1. J Infect Dis 1999;179:1116-23.
  15. Murray M. P-450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992;23:132-46.
  16. Krecic-Shepard ME, Barnas CR, Slimko J, Jones MP, Schwartz JB. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol 2000;40: 219-30.
  17. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-83.
  18. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P-450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997;61:331-9.
  19. Centers for Disease Control and Prevention. Notice to readers: updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis in patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2000;49:185-9.
  20. Jenne JW. Effect of disease states on theophylline elimination. J Allergy Clin Immunol 1986;78:727-35.
  21. Chow H, Tang Y, Brookshier G, Liang B, Watson R. The effect of chronic retrovirus infection and immune dysfunction on the P-450-mediated activation of acetaminophen in mouse liver microsome. Biopharm Drug Dispos 1998;19:9-15.
  22. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993;44:707-15.
  23. Bergamini A, Faggioli E, Bolacchi F, et al. Enhanced production of tumor necrosis factor-a and interleukin-6 due to prolonged response to epopolysaccharide in human macrophages infected in vitro with human immunodeficiency virus type 1. J Infect Dis 1999;179:832-42.
  24. Metabolic Solutions Inc. Erythromycin breath test assay product information. Nashau, NH.
  25. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996;24:475-90.
  26. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhes JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990;48:120-9.
  27. Lown KS, Thummel KE, Benedict PE, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995;57:16-24.
  28. Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999;27:161-6.
  29. Brophy DF, Israel DS, Pastor A, et al. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob Agents Chemother 2000;44: 978-84.
  30. Polk RE, Brophy DF, Israel DS, et al. Pharmacokinetic interaction between amprenavir and rifabutin and rifampin in healthy males. Antimicrob Agents Chemother, in press.
  31. Polk RE, Crouch MA, Israel DS, et al. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy 1999;19:1378-84.
  32. Wagner D. CYP3A4 and the erythromycin breath test [letter]. Clin Pharmacol Ther 1998;64:129.
  33. Merck & Co. Crixivan (indinavir) package insert. West Point, PA;December 1999.
  34. Agouron Pharmaceuticals Inc. Viracept (nelfinavir) package insert. La Jolla, CA;October 1997.
  35. Gotzkowsky SK, Weidler J, Tonkin J, et al. Cytochrome P450 (CYP) 3A4 and 2D6 activities are decreased in HIV-infected subjects [abstr]. Proceedings and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy, San Francisco, September 26-29, 1999.
  36. Farrel GC. Drug metabolism in extrahepatic diseases. Pharmacol Ther 1987;35:375-404.
  37. Emilie D, Fior R, Jarrousse B, et al. Cytokines in HIV infection. Int J Immunopharmacol 1994;16:391-6.
  38. Piscitelli SC, Vogel S, Figg WD, et al. Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus. Pharmacotherapy 1998;18:1212-16.
  39. Kinirons MT, O'Shea D, Kim RB, et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe for cytochrome P450A. Clin Pharmacol Ther 1999;66:224-31.
  40. De Wildt SN, Kearns GL, Leeder JS, van der Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485-505.
  41. Cheng CL, Smith DE, Carver PL, et al. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther 1997;61:531-43.
  42. Lamson M, MacGregor T, Riska P, et al. Neviripine induces both CYP3A4 and CYP2B6 metabolic pathways [abstr]. Presented at the 100th annual meeting of the American Society for Clinical Pharmacology and Therapeutics, San Antonio, March 18-20, 1999.
  43. Strolin Benedetti M, Bani M. Metabolism-based drug interactions involving oral azole antifungals in humans. Drug Metab Rev 1999;31:665-717.
  44. Davit B, Reynolds K, Yuan R, et al. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol 1999;39:899-910.
  45. Hsu A, Lal R, Bertz R, et al. ABT-378 and ritonavir exposures are not predicted by the erythromycin breath test (ERMBT) [abstr]. Proceedings and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy, San Francisco, September 26-29, 1999.
  46. Wynn H, Shelton MJ, Bartos L, DiFrancesco R, Hewitt RG. Grapefruit juice increases gastric pH, but does not affect indinavir exposure in HIV patients [abstr]. Proceedings and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy, San Francisco, September 26-29, 1999.
  47. Fletcher CV, Kakuda TN, Anderson PL, Henry K, Schacker T, Brundage RC. Viral dynamics of concentration-targeted vs. standard-dose therapy with zidovudine, lamivudine and indinavir [abstr]. Proceedings and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy, San Francisco, September 26-29, 1999.
  48. Descampes D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000;283:205-11.
  49. Havilar DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000;283: 229-34.
  50. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62:248-60.
  51. Kim RB, Fromm NE, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-94.
  52. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;37:3594-601.
  53. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:203-9.
  54. Krecic-Shepard ME, Barnas CR, Slimko L, Gorski JC, Wainer IW, Schwartz J. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther 1999;66:40-50.
  55. Yeun GJ, Anderson R, Sandoval T, Wu E, Shetty BV, Kerr BM. The pharmacokinetics of nelfinavir administered alone and with rifampin in healthy volunteers [abstr]. Presented at the 98th meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, March 5-8, 1997.